Nurix Therapeutics, Inc. (NRIX) Misses Q2 EPS by 8c

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q2 EPS of ($0.71), $0.08 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $12.09 million versus the consensus estimate of $22.11 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks
• Molson Coors Brewing (TAP) dropped from S&P 500